Antihypertensive Therapy and Quality of Life: a Comparison of Atenolol, Captopril, Enalapril and Propranolol
Overview
Affiliations
This randomized, double-blind parallel study compared the effects of atenolol, captopril, enalapril and propranolol in 360 men with mild-to-moderate essential hypertension. Patients were titrated until diastolic blood pressure (Korotkoff phase V) decreased by at least 10 mmHg or to 90 mmHg or less. Quality of life assessments, based on validated psychometric questionnaires and objective measurements of cognitive function, occurred after three study phases: placebo run-in (3-5 weeks), titration (1-4 weeks), and maintenance (4 weeks). After four weeks of maintenance therapy, atenolol, captopril and enalapril generally had equivalent effects on quality of life, as measured by psychometric questionnaires, whereas propranolol consistently evidenced worsening or less improvement. Global scores of distressing psychological symptoms differed as a function of specific treatment (P = 0.01), with improvements significantly better for the atenolol, captopril and enalapril groups as compared with the propranolol group. There were no statistically significant differences among treatments for changes in cognitive function at maintenance. Thus, the quality of life questionnaires differentiated among drugs of the same class, indicating that selection among antihypertensive drugs should be based on their specific qualities, not on general class characteristics.
Choi J, Choi S, Kang D, Shin H, Lee M, Hwang J J Vet Sci. 2023; 24(2):e26.
PMID: 37012034 PMC: 10071283. DOI: 10.4142/jvs.22275.
Yasar S, Lin F, Fried L, Kawas C, Sink K, DeKosky S Alzheimers Dement. 2012; 8(3):188-95.
PMID: 22465175 PMC: 3341535. DOI: 10.1016/j.jalz.2011.03.010.
A review of the safety and efficacy of nebivolol in the mildly hypertensive patient.
Cockcroft J Vasc Health Risk Manag. 2008; 3(6):909-17.
PMID: 18200810 PMC: 2350132.
Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.
Agabiti Rosei E, Rizzoni D Drugs. 2007; 67(8):1097-107.
PMID: 17521213 DOI: 10.2165/00003495-200767080-00001.
Neuropsychiatric consequences of cardiovascular medications.
Huffman J, Stern T Dialogues Clin Neurosci. 2007; 9(1):29-45.
PMID: 17506224 PMC: 3181843.